BKA
ACAD icon

Brick & Kyle Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Brick & Kyle Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-300
Closed -$10K – 100
2017
Q1 		$10K Buy
+300
New +$10.6K 0.01% 342

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Brick & Kyle Associates's ACAD Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Acadia Pharmaceuticals (ACAD) in Q2 2017, closing a stake of 300 shares — an estimated $10K sold.

Brick & Kyle Associates first reported a position in ACAD in Q1 2017 and held it in 1 quarter. The position peaked at $10K in Q1 2017. 203 funds tracked by Wall St. Rank hold ACAD as of Q2 2017.

  • Brick & Kyle Associates reported no remaining Acadia Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Brick & Kyle Associates sold 300 Acadia Pharmaceuticals shares in Q2 2017, an estimated $10K.
  • Brick & Kyle Associates first reported a position in Acadia Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Brick & Kyle Associates's Acadia Pharmaceuticals position peaked at $10K in Q1 2017.
  • 203 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.